- Home
- REGN vs SMFG Comparison
REGN vs SMFG Comparison
Compare REGN & SMFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- SMFG
- Stock Information
- Founded
- REGN 1988
- SMFG 2002
- Country
- REGN United States
- SMFG Japan
- Employees
- REGN N/A
- SMFG N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- SMFG Commercial Banks
- Sector
- REGN Health Care
- SMFG Finance
- Exchange
- REGN Nasdaq
- SMFG Nasdaq
- Market Cap
- REGN 110.0B
- SMFG 97.7B
- IPO Year
- REGN 1991
- SMFG 1949
- Fundamental
- Price
- REGN $701.85
- SMFG $14.05
- Analyst Decision
- REGN Buy
- SMFG
- Analyst Count
- REGN 24
- SMFG 0
- Target Price
- REGN $1,054.00
- SMFG N/A
- AVG Volume (30 Days)
- REGN 920.8K
- SMFG 1.1M
- Earning Date
- REGN 01-31-2025
- SMFG 01-30-2025
- Dividend Yield
- REGN N/A
- SMFG 2.90%
- EPS Growth
- REGN 15.31
- SMFG 62.30
- EPS
- REGN 40.43
- SMFG 1.90
- Revenue
- REGN $13,847,100,000.00
- SMFG $29,024,781,023.00
- Revenue This Year
- REGN $10.20
- SMFG N/A
- Revenue Next Year
- REGN $4.16
- SMFG $6.26
- P/E Ratio
- REGN $17.36
- SMFG $12.18
- Revenue Growth
- REGN 5.72
- SMFG 12.07
- 52 Week Low
- REGN $693.00
- SMFG $9.43
- 52 Week High
- REGN $1,211.20
- SMFG $15.56
- Technical
- Relative Strength Index (RSI)
- REGN 27.80
- SMFG 44.06
- Support Level
- REGN $693.00
- SMFG $13.96
- Resistance Level
- REGN $745.00
- SMFG $15.02
- Average True Range (ATR)
- REGN 21.29
- SMFG 0.18
- MACD
- REGN 0.05
- SMFG -0.17
- Stochastic Oscillator
- REGN 8.20
- SMFG 6.79
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
About SMFG Sumitomo Mitsui Financial Group Inc Unsponsored (Japan)
Sumitomo Mitsui Financial Group is roughly tied with Mizuho Financial Group for the status of Japan's second-largest bank after Mitsubishi UFJ Financial Group. As of March 2024, its market share of domestic loans was 7.2%, compared with 8.0% for MUFG. It has a larger consumer finance business than the other two megabanks, owning 100% of the Promise business and SMBC Card. It also controls one of Japan's largest leasing companies and SMBC Aviation Capital, one of the top five aircraft lessors globally. In securities, its SMBC Nikko unit is Japan's third-largest retail broker, although SMFG has lagged somewhat in institutional securities business and asset management.